Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ACXP
ACURX PHARMACEUTICALS, INC.
NASDAQ
$1.44
▼ DOWN 1.37% (-0.02)

KEY STATISTICS

Market Cap$6.19 M
52w High$8.34
52w Low$1.31
Dividend Yield—
Frequency—
P/E-0.36
Volume69.74K
Shares Out.4.30M

COMPANY

LEADERSHIP

David Luci
CHIEF EXECUTIVE
David Luci

COMPENSATION 2026

Salary$537,508
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$0
Total$1,431,383

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 25, 2021
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
4

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.—
NOV
11
WED

SPLIT RECORD

DATETYPERATIO
2025-08-05Reverse1:20

PRICE

$1.44 ▼ DOWN 1.37% (−$0.02)
OVERLAYS
$1.43$1.44$1.45$1.4710:21 AM11:17 AM12:14 PM1:10 PM2:06 PM3:03 PM3:59 PM1.44

About Acurx Pharmaceuticals, Inc.

https://www.acurxpharma.com ↗

Acurx Pharmaceuticals, Inc. is a clinical-stage biopharma developing antibiotics like ibezapolstat for bacterial infections, including C. difficile and resistant gram-positive bacteria, headquartered in Staten Island since 2017.

INDUSTRY

Biotechnology

A PRODUCT ACURX PHARMACEUTICALS, INC. IS KNOWN FOR

ibezapolstat
ibezapolstat

Ibezapolstat is an oral antibiotic targeting DNA polymerase IIIC in Gram-positive bacteria, developed for CDI, completed Phase 2b, and poised for Phase 3 trials as Acurx's leading pipeline candidate.

COMPETITORS

COMPETITOR
IMRN COMPARE
MCRB COMPARE
MRK COMPARE
PFE COMPARE
SMMT COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
1
LISTED HERE
1
RANKED BY POSITION SIZE
VXF
0.00% · 31.1K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
28.06%
HOLDERS
17
TOP 12 OF 17 · RANKED BY POSITION SIZE
Armistice Capital, LLC
1.1M sh · $550.92K
Jane Street Group, LLC
54.6K sh · $202.72K
Blackrock Inc.
27.5K sh · $61.88K
Geode Capital Management, LLC
24.8K sh · $92.08K
Advisor Group Holdings, Inc.
7.6K sh · $2.43K
Morgan Stanley
6.5K sh · $24.11K
Wells Fargo & Company/Mn
2.3K sh · $8.53K
Western Wealth Management, LLC
1.3K sh · $4.92K
Cutler Group LLC / Ca
1.2K sh · $2K
Tower Research Capital LLC (Trc)
1.0K sh · $3.83K
Barclays Plc
380 sh · $1.41K
Group One Trading, L.P.
245 sh · $909

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book4
Overall Score2

INSIDER TRADES

★
DIRECTOR
Sailer Carl
Purchase · 2.1K shares
2026-04-20
★
DIRECTOR
Donohue James J.
Purchase · 2.1K shares
2026-04-20
★
DIRECTOR
HARRISON THOMAS L
Purchase · 2.1K shares
2026-04-20
★
DIRECTOR
DEAN JACK H
Purchase · 2.1K shares
2026-04-20

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
1 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
BCDA$1.15COMPARE
BCLI$1.12COMPARE
KPRX$2.62COMPARE
APRE$0.84COMPARE
INAB$1.03COMPARE
ADIL$5.60COMPARE
APVO$2.37COMPARE
CELZ$1.14COMPARE